In another sign that the coronavirus pandemic is fundamentally interrupting the way biopharma conducts business, drug makers are grounding the employees who market and sell their products to physicians and hospitals.
On Sunday, Amarin, the maker of the heart drug Vascepa, said it was implementing a two-week suspension of all “face-to-face interactions” between its salespeople and physician offices. The restriction will be in place until March 30.
Amgen and Merck have also instructed their respective salesforces to halt all in-person meetings with physicians and hospitals.
About the Author Reprints
Maybe this will curb blatant Doctor-bribing ….. now sales must pretty much all be done on-line, and PrintSCreen and a paper-trail certainly promote honesty and fairness …..